412 related articles for article (PubMed ID: 11865071)
1. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
2. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
3. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex.
Melville MW; McClellan AJ; Meyer AS; Darveau A; Frydman J
Mol Cell Biol; 2003 May; 23(9):3141-51. PubMed ID: 12697815
[TBL] [Abstract][Full Text] [Related]
4. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
5. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
6. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
Lonergan KM; Iliopoulos O; Ohh M; Kamura T; Conaway RC; Conaway JW; Kaelin WG
Mol Cell Biol; 1998 Feb; 18(2):732-41. PubMed ID: 9447969
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.
Okuda H; Saitoh K; Hirai S; Iwai K; Takaki Y; Baba M; Minato N; Ohno S; Shuin T
J Biol Chem; 2001 Nov; 276(47):43611-7. PubMed ID: 11574546
[TBL] [Abstract][Full Text] [Related]
8. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
Pioli PA; Rigby WF
J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
[TBL] [Abstract][Full Text] [Related]
9. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
11. The von Hippel-Lindau tumor suppressor protein.
Ivan M; Kaelin WG
Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
13. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.
Feldman DE; Thulasiraman V; Ferreyra RG; Frydman J
Mol Cell; 1999 Dec; 4(6):1051-61. PubMed ID: 10635329
[TBL] [Abstract][Full Text] [Related]
14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
17. Identification of Elongin C and Skp1 sequences that determine Cullin selection.
Yan Q; Kamura T; Cai Y; Jin J; Ivan M; Mushegian A; Conaway RC; Conaway JW
J Biol Chem; 2004 Oct; 279(41):43019-26. PubMed ID: 15280393
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
[TBL] [Abstract][Full Text] [Related]
19. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
Ohh M; Takagi Y; Aso T; Stebbins CE; Pavletich NP; Zbar B; Conaway RC; Conaway JW; Kaelin WG
J Clin Invest; 1999 Dec; 104(11):1583-91. PubMed ID: 10587522
[TBL] [Abstract][Full Text] [Related]
20. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein.
Pause A; Peterson B; Schaffar G; Stearman R; Klausner RD
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9533-8. PubMed ID: 10449727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
